Browse TREX1

Summary
SymbolTREX1
Namethree prime repair exonuclease 1
Aliases DRN3; Aicardi-Goutieres syndrome 1; CRV; HERNS; 3' repair exonuclease 1; 3'-5' exonuclease TREX1; DNase III; ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Cytoplasm, cytosol. Endoplasmic reticulum membrane; Peripheral membrane protein. Note=Retained in the cytoplasm through the C-terminal region (By similarity). In response to DNA damage, translocates to the nucleus where it is specifically recruited to replication foci. Translocation to the nucleus also occurs during GZMA-mediated cell death.
Domain -
Function

Major cellular 3'-to-5' DNA exonuclease which digests single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) with mismatched 3' termini. Prevents cell-intrinsic initiation of autoimmunity. Acts by metabolizing DNA fragments from endogenous retroelements, including L1, LTR and SINE elements. Unless degraded, these DNA fragments accumulate in the cytosol and activate the IFN-stimulatory DNA (ISD) response and innate immune signaling. Prevents chronic ATM-dependent checkpoint activation, by processing ssDNA polynucleotide species arising from the processing of aberrant DNA replication intermediates. Inefficiently degrades oxidized DNA, such as that generated upon antimicrobial reactive oxygen production or upon absorption of UV light. During GZMA-mediated cell death, contributes to DNA damage in concert with NME1. NME1 nicks one strand of DNA and TREX1 removes bases from the free 3' end to enhance DNA damage and prevent DNA end reannealing and rapid repair.

> Gene Ontology
 
Biological Process -
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04623 Cytosolic DNA-sensing pathway
Reactome R-HSA-1834949: Cytosolic sensors of pathogen-associated DNA
R-HSA-3270619: IRF3-mediated induction of type I IFN
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-3248023: Regulation by TREX1
R-HSA-3134975: Regulation of innate immune responses to cytosolic DNA
R-HSA-1834941: STING mediated induction of host immune responses
Summary
SymbolTREX1
Namethree prime repair exonuclease 1
Aliases DRN3; Aicardi-Goutieres syndrome 1; CRV; HERNS; 3' repair exonuclease 1; 3'-5' exonuclease TREX1; DNase III; ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TREX1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TREX1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28598415Breast Carcinoma; Colorectal CarcinomaInhibit immunity (infiltration); Resistant to immunotherapy.We show that the DNA exonuclease Trex1 is induced by radiation doses above 12-18 Gy in different cancer cells, and attenuates their immunogenicity by degrading DNA that accumulates in the cytosol upon radiation. Repeated irradiation at doses that do not induce Trex1 amplifies interferon-β production, resulting in recruitment and activation of Batf3-dependent dendritic cells.
Summary
SymbolTREX1
Namethree prime repair exonuclease 1
Aliases DRN3; Aicardi-Goutieres syndrome 1; CRV; HERNS; 3' repair exonuclease 1; 3'-5' exonuclease TREX1; DNase III; ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TREX1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.67; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolTREX1
Namethree prime repair exonuclease 1
Aliases DRN3; Aicardi-Goutieres syndrome 1; CRV; HERNS; 3' repair exonuclease 1; 3'-5' exonuclease TREX1; DNase III; ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TREX1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0780.817
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1530.923
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2470.833
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1440.63
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2680.887
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0070.998
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8490.559
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1380.604
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0240.798
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TREX1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTREX1
Namethree prime repair exonuclease 1
Aliases DRN3; Aicardi-Goutieres syndrome 1; CRV; HERNS; 3' repair exonuclease 1; 3'-5' exonuclease TREX1; DNase III; ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TREX1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTREX1
Namethree prime repair exonuclease 1
Aliases DRN3; Aicardi-Goutieres syndrome 1; CRV; HERNS; 3' repair exonuclease 1; 3'-5' exonuclease TREX1; DNase III; ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TREX1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TREX1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTREX1
Namethree prime repair exonuclease 1
Aliases DRN3; Aicardi-Goutieres syndrome 1; CRV; HERNS; 3' repair exonuclease 1; 3'-5' exonuclease TREX1; DNase III; ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TREX1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTREX1
Namethree prime repair exonuclease 1
Aliases DRN3; Aicardi-Goutieres syndrome 1; CRV; HERNS; 3' repair exonuclease 1; 3'-5' exonuclease TREX1; DNase III; ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TREX1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTREX1
Namethree prime repair exonuclease 1
Aliases DRN3; Aicardi-Goutieres syndrome 1; CRV; HERNS; 3' repair exonuclease 1; 3'-5' exonuclease TREX1; DNase III; ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TREX1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTREX1
Namethree prime repair exonuclease 1
Aliases DRN3; Aicardi-Goutieres syndrome 1; CRV; HERNS; 3' repair exonuclease 1; 3'-5' exonuclease TREX1; DNase III; ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TREX1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.